Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Rating of “Hold” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has been given a consensus rating of “Hold” by the six brokerages that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $51.00.

Several brokerages have issued reports on OMCL. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company lowered their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday.

Omnicell Stock Up 0.5 %

OMCL stock opened at $34.88 on Friday. The stock’s fifty day simple moving average is $39.94 and its two-hundred day simple moving average is $42.98. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.75. The stock has a market cap of $1.63 billion, a P/E ratio of 129.19, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts expect that Omnicell will post 1.09 EPS for the current year.

Institutional Trading of Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Omnicell by 22.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company’s stock valued at $5,306,000 after purchasing an additional 21,847 shares during the period. Squarepoint Ops LLC increased its stake in Omnicell by 286.4% in the 4th quarter. Squarepoint Ops LLC now owns 149,717 shares of the company’s stock worth $6,665,000 after acquiring an additional 110,966 shares during the last quarter. Two Sigma Investments LP increased its stake in Omnicell by 44.2% in the 4th quarter. Two Sigma Investments LP now owns 141,738 shares of the company’s stock worth $6,310,000 after acquiring an additional 43,471 shares during the last quarter. Toronto Dominion Bank bought a new position in Omnicell in the 4th quarter worth about $30,637,000. Finally, Point72 Hong Kong Ltd bought a new position in Omnicell in the 4th quarter worth about $101,000. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.